Company intelligence / Profile preview

AlpineBrook Capital GP 1 Limited

Cayman Islands

Ownership: Private
Development stage: Other

Overview

AlpineBrook Capital GP 1 Limited is an investment entity that provided the majority of approximately $17 million funding to NKGen Biotech, Inc. for its acquisition of a 65% equity stake in NKMax Co., Ltd. in September 2025. It has also extended prior funding advances totaling around $3 million to NKGen in 2025, convertible notes, and additional loans to support NKGen's clinical development of NK cell therapies.

Industry: Investors

Partnerships

NKGen Biotech, Inc.

Beyond the preview

Go deeper on AlpineBrook Capital GP 1 Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlpineBrook Capital GP 1 Limited.

Explore the full profile